Neuroprotective agents in glaucoma therapy: Recent developments and future directions

Expert Review of Ophthalmology

Volumn 5, Issue 5, 2010, Pages 627-636

  Chua, Brian ^a,b   Goldberg, Ivan ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Eye Associates   (Australia)

^c SYDNEY EYE HOSPITAL   (Australia)

Author keywords

apoptosis; brimonidine; excitotoxicity; glaucoma; memantine; neuronal death; neuroprotection; retinal ganglion cell

Indexed keywords

ALPHA TOCOPHEROL; AMINOGUANIDINE; AMYLOID BETA PROTEIN ANTIBODY; BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CALPAIN 4 INHIBITOR; CASPASE 3 INHIBITOR; CYSTEINE PROTEINASE INHIBITOR; DEXTROMETHORPHAN; DILTIAZEM; FLUNARIZINE; FLUPIRTINE; GINKGO BILOBA EXTRACT; GLATIRAMER; GLC 756; LOMERIZINE; MELATONIN; MEMANTINE; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; NIFEDIPINE; NILVADIPINE; PLACEBO; RILUZOLE; SJA 6017; TEPRENONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ALZHEIMER DISEASE; BLINDNESS; CLINICAL TRIAL; COMORBIDITY; DEGENERATIVE DISEASE; DRUG DOSE COMPARISON; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE FIBER; NEUROPROTECTION; NONHUMAN; OPEN ANGLE GLAUCOMA; OPTIC NERVE LESION; RETINA GANGLION CELL; REVIEW; VISUAL DISORDER;

EID: 77957930218     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.10.55     Document Type: Review

References (119)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90(3), 262-267 (2006).
2. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest. Ophthalmol. Vis. Sci. 36(5), 774-786 (1995).
3. Nickells RW. Retinal ganglion cell death in glaucoma: the how, the why, and the maybe. J. Glaucoma 5(5), 345-356 (1996).
4. Whitmore AV, Libby RT, John SW. Glaucoma: thinking in new ways-a role for autonomous axonal self-destruction and other compartmentalised processes? Prog. Retin. Eye Res. 24(6), 639-662 (2005).
5. Yucel YH, Zhang Q, Weinreb RN, Kaufman PL, Gupta N. Atrophy of relay neurons in magno- and parvocellular layers in the lateral geniculate nucleus in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 42(13), 3216-3222 (2001).
6. Yucel YH, Zhang Q, Gupta N, Kaufman PL, Weinreb RN. Loss of neurons in magnocellular and parvocellular layers of the lateral geniculate nucleus in glaucoma. Arch. Ophthalmol. 118(3), 378-384 (2000).
7. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am. J. Ophthalmol. 130(4), 429-440 (2000).
8. Comparison of glaucomatous progression between untreated patients with normaltension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am. J. Ophthalmol. 126(4), 487-497 (1998).
9. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch. Ophthalmol. 121(1), 48-56 (2003). (Pubitemid 36401765)
10. Schwartz M, Belkin M, Yoles E, Solomon A. Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. J. Glaucoma 5(6), 427-432 (1996).
11. Schwartz M. Lessons for glaucoma from other neurodegenerative diseases: can one treatment suit them all? J. Glaucoma 14(4), 321-323 (2005).
12. Schwartz M, London A. Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation. Prog. Brain Res. 173, 375-384 (2008).
13. Schwartz M, Yoles E, Levin LA. Axogenic and somagenic neurodegenerative diseases: definitions and therapeutic implications. Mol. Med. Today 5(11), 470-473 (1999).
14. Lynch DR, Dawson TM. Secondary mechanisms in neuronal trauma. Curr. Opin. Neurol. 7(6), 510-516 (1994)
15. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv. Ophthalmol. 53(Suppl. 1), S3-S10 (2008).
16. Johnson EC, Guo Y, Cepurna WO, Morrison JC. Neurotrophin roles in retinal ganglion cell survival: lessons from rat glaucoma models. Exp. Eye Res. 88(4), 808-815 (2009).
17. Quigley HA, McKinnon SJ, Zack DJ et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest. Ophthalmol. Vis. Sci. 41(11), 3460-3466 (2000).
18. Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 41(3), 764-774 (2000).
19. Flammer J, Orgul S, Costa VP et al. The impact of ocular blood flow in glaucoma. Prog. Retin. Eye Res. 21(4), 359-393 (2002).
20. Mozaffarieh M, Grieshaber MC, Flammer J. Oxygen and blood flow: players in the pathogenesis of glaucoma. Mol. Vis. 14, 224-233 (2008). (Pubitemid 351223391)
21. Kong GY, Van Bergen NJ, Trounce IA, Crowston JG. Mitochondrial dysfunction and glaucoma. J. Glaucoma 18(2), 93-100 (2009).
22. Li D, Sun F, Wang K. Protein profile of aging and its retardation by caloric restriction in neural retina. Biochem. Biophys. Res. Commun. 318(1), 253-258 (2004).
23. Dreyer EB. A proposed role for excitotoxicity in glaucoma. J. Glaucoma 7(1), 62-67 (1998).
24. Stuiver BT, Douma BR, Bakker R, Nyakas C, Luiten PG. In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: combined therapy and temporal course of protection. Neurodegeneration 5(2), 153-159 (1996).
25. 2+ channels and in gerbil global cerebral ischaemia. Eur. J. Pharmacol. 299(1-3), 103-112 (1996).
26. Lipton SA, Choi YB, Pan ZH et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitrosocompounds. Nature 364(6438), 626-632 (1993).
27. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58(4), 495-505 (2005).
28. Nucci C, Tartaglione R, Rombola L, Morrone LA, Fazzi E, Bagetta G. Neurochemical evidence to implicate elevated glutamate in the mechanisms of high intraocular pressure (IOP)-induced retinal ganglion cell death in rat. Neurotoxicology 26(5), 935-941 (2005).
29. Russo R, Cavaliere F, Rombola L et al. Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection. Prog. Brain Res. 173, 575-582 (2008).
30. Guo L, Salt TE, Luong V et al. Targeting amyloid-b in glaucoma treatment. Proc. Natl Acad. Sci. USA 104(33), 13444-13449 (2007).
31. Serrano-Pozo A, William CM, Ferrer Iet al. Beneficial effect of human antiamyloid- b active immunization on neurite morphology and tau pathology. Brain 133(Pt 5), 1312-1327 (2010).
32. O'Reilly AM, Currie RW, Clarke DB. HspB1 (Hsp 27) expression and neuroprotection in the retina. Mol. Neurobiol. DOI: 10.1007/s12035-010- 8143-8153 (2010) (Epub ahead of print).
33. Wax MB, Tezel G, Kawase K, Kitazawa Y. Serum autoantibodies to heat shock proteins in glaucoma patients from Japan and the United States. Ophthalmology 108(2), 296-302 (2001).
34. Junier MP. What role(s) for TGFa in the central nervous system? Prog. Neurobiol. 62(5), 443-473 (2000).
35. Liu X, Clark AF, Wordinger RJ. Expression of ciliary neurotrophic factor (CNTF) and its tripartite receptor complex by cells of the human optic nerve head. Mol. Vis. 13, 758-763 (2007).
36. Smith C, Berry M, Clarke WE, Logan A. Differential expression of fibroblast growth factor-2 and fibroblast growth factor receptor 1 in a scarring and nonscarring model of CNS injury in the rat. Eur. J. Neurosci. 13(3), 443-456 (2001).
37. Gris P, Tighe A, Levin D, Sharma R, Brown A. Transcriptional regulation of scar gene expression in primary astrocytes. Glia 55(11), 1145-1155 (2007).
38. Hernandez MR, Miao H, Lukas T. Astrocytes in glaucomatous optic neuropathy. Prog. Brain Res. 173, 353-373 (2008).
39. Leibinger M, Muller A, Andreadaki A, Hauk TG, Kirsch M, Fischer D. Neuroprotective and axon growthpromoting effects following inflammatory stimulation on mature retinal ganglion cells in mice depend on ciliary neurotrophic factor and leukemia inhibitory factor. J. Neurosci. 29(45), 14334-14341 (2009).
40. Rose K, Litterscheid S, Klumpp S, Krieglstein J. Fibroblast growth factor 2 requires complex formation with ATP for neuroprotective activity. Neuroscience 164(4), 1695-1700 (2009).
41. Kumar A, Singh RL, Babu GN. Cell death mechanisms in the early stages of acute glutamate neurotoxicity. Neurosci. Res. 66(3), 271.278 (2009).
42. Green DR. Apoptotic pathways: the roads to ruin. Cell 94(6), 695.698 (1998).
43. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 79(2), 189.192 (1994).
44. Levin LA, Schlamp CL, Spieldoch RL, Geszvain KM, Nickells RW. Identification of the Bcl.2 family of genes in the rat retina. Invest. Ophthalmol. Vis. Sci. 38(12), 2545.2553 (1997).
45. Quigley HA. Neuronal death in glaucoma. Prog. Retin. Eye Res. 18(1), 39.57 (1999).
46. Ko ML, Hu DN, Ritch R, Sharma SC. The combined effect of brain-derived neurotrophic factor and a free radical scavenger in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 41(10), 2967.2971 (2000).
47. Bai Y, Xu J, Brahimi F, Zhuo Y, Sarunic MV, Saragovi HU. An agonistic anti-TrkB mAb, but not BDNF, causes sustained TrkB activation, delays RGC death, and protects the retinal structure in optic nerve axotomy and in glaucoma. Invest. Ophthalmol. Vis. Sci. DOI: 10.1167/ iovs.09-5032 (2010) (Epub ahead of print).
48. Shi Z, Rudzinski M, Meerovitch K et al. A2-macroglobulin is a mediator of retinal ganglion cell death in glaucoma. J. Biol. Chem. 283(43), 29156.29165 (2008).
49. Lebrun-Julien F, Morquette B, Douillette A, Saragovi HU, Di Polo A. Inhibition of p75(NTR) in glia potentiates TrkAmediated survival of injured retinal ganglion cells. Mol. Cell. Neurosci. 40(4), 410.420 (2009).
50. Fu QL, Hu B, Wu W, Pepinsky RB, Mi S, So KF. Blocking LINGO-1 function promotes retinal ganglion cell survival following ocular hypertension and optic nerve transection. Invest. Ophthalmol. Vis. Sci. 49(3), 975.985 (2008).
51. Fu QL, Li X, Yip HK et al. Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. Neuroscience 162(2), 375.382 (2009).
52. Fitzgerald M, Payne SC, Bartlett CA, Evill L, Harvey AR, Dunlop SA. Secondary retinal ganglion cell death and the neuroprotective effects of the calcium channel blocker lomerizine. Invest. Ophthalmol. Vis. Sci. 50(11), 5456.5462 (2009).
53. Gasser P, Flammer J. Short- and long-term effect of nifedipine on the visual field in patients with presumed vasospasm. J. Int. Med. Res. 18(4), 334.339 (1990).
54. 2+-antagonist on visual field in low-tension glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 227(5), 408.412 (1989).
55. Koseki N, Araie M, Tomidokoro A et al. A placebo-controlled 3.year study of a calcium blocker on visual field and ocular circulation in glaucoma with low.normal pressure. Ophthalmology 115(11), 2049.2057 (2008).
56. Graham SL, Drance SM. Nocturnal hypotension: role in glaucoma progression. Surv. Ophthalmol. 43(Suppl. 1), S10.S16 (1999).
57. Young AJ, Johnson S, Steffens DC, Doraiswamy PM. Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr. 12(1), 62.68 (2007).
58. Papucci L, Schiavone N, Witort E et al. Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J. Biol. Chem. 278(30), 28220.28228 (2003).
59. Nucci C, Tartaglione R, Cerulli A et al. Retinal damage caused by high intraocular pressure-induced transient ischemia is prevented by coenzyme Q10 in rat. Int. Rev. Neurobiol. 82, 397.406 (2007).
60. Cheung W, Guo L, Cordeiro MF. Neuroprotection in glaucoma: drug-based approaches. Optom. Vis. Sci. 85(6), 406.416 (2008).
61. Nakajima Y, Inokuchi Y, Nishi M, Shimazawa M, Otsubo K, Hara H. Coenzyme Q10 protects retinal cells against oxidative stress in vitro and in vivo. Brain Res. 1226, 226.233 (2008).
62. Aydemir O, Naziroglu M, Celebi S, Yilmaz T, Kukner AS. Antioxidant effects of a-, g- and succinate-tocopherols in guinea pig retina during ischemia-reperfusion injury. Pathophysiology 11(3), 167.171 (2004).
63. Engin KN. a-tocopherol: looking beyond an antioxidant. Mol. Vis. 15, 855.860 (2009).
64. Engin KN, Engin G, Kucuksahin H, Oncu M, Guvener B. Clinical evaluation of the neuroprotective effect of a-tocopherol against glaucomatous damage. Eur. J. Ophthalmol. 17(4), 528.533 (2007).
65. Belforte NA, Moreno MC, de Zavalia Nsoh et al. Melatonin: a novel neuroprotectant for the treatment of glaucoma. J. Pineal Res. 48(4), 353.364 (2010).
66. Lundmark PO, Pandi-Perumal SR, Srinivasan V, Cardinali DP, Rosenstein RE. Melatonin in the eye: implications for glaucoma. Exp. Eye Res. 84(6), 1021.1030 (2007).
67. Wang X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci. Ther. 15(4), 345.357 (2009).
68. Tang Q, Hu Y, Cao Y. Neuroprotective effect of melatonin on retinal ganglion cells in rats. J. Huazhong Univ. Sci. Technolog. Med. Sci. 26(2), 235.237, 253 (2006).
69. Hirooka K, Tokuda M, Miyamoto O, Itano T, Baba T, Shiraga F. The ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma. Curr. Eye Res. 28(3), 153.157 (2004).
70. Ma K, Xu L, Zhang H, Zhang S, Pu M, Jonas JB. The effect of ginkgo biloba on the rat retinal ganglion cell survival in the optic nerve crush model. Acta Ophthalmol. 88(5), 553.557 (2010).
71. Ma K, Xu L, Zhan H, Zhang S, Pu M, Jonas JB. Dosage dependence of the effect of ginkgo biloba on the rat retinal ganglion cell survival after optic nerve crush. Eye (Lond.) 23(7), 1598.1604 (2009).
72. Quaranta L, Bettelli S, Uva MG, Semeraro F, Turano R, Gandolfo E. Effect of ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology 110(2), 359.362; discussion 362.354 (2003).
73. Khoury R, Cross JM, Girkin CA, Owsley C, McGwin G Jr. The association between self-reported glaucoma and ginkgo biloba use. J. Glaucoma 18(7), 543.545 (2009).
74. Pang IH, Johnson EC, Jia L et al. Evaluation of inducible nitric oxide synthase in glaucomatous optic neuropathy and pressure-induced optic nerve damage. Invest. Ophthalmol. Vis. Sci. 46(4), 1313.1321 (2005).
75. Neufeld AH. Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma. Brain Res. Bull. 62(6), 455.459 (2004).
76. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348(14), 1333.1341 (2003).
77. Ju WK, Kim KY, Angert M et al. Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. Invest. Ophthalmol. Vis. Sci. 50(2), 707.716 (2009).
78. Kim JH, Lee NY, Jung SW, Park CK. Expression of N-methyl-d-aspartate receptor 1 in rats with chronic ocular hypertension. Neuroscience 149(4), 908.916 (2007).
79. Hare WA, WoldeMussie E, Lai RK et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: functional measures. Invest. Ophthalmol. Vis. Sci. 45(8), 2625.2639 (2004). (Pubitemid 38998859)
80. Hare WA, WoldeMussie E, Weinreb RN et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: structural measures. Invest. Ophthalmol. Vis. Sci. 45(8), 2640.2651 (2004). (Pubitemid 38998860)
81. Sattler MB, Williams SK, Neusch C et al. Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis. Am. J. Pathol. 173(5), 1496.1507 (2008).
82. 2+ block via activation of voltage independent potassium channels. Rapid communication. J. Neural Transm. 106(9.10), 857.867 (1999).
83. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 330(9), 585.591 (1994).
84. Lacomblez L, Bensimon G, Leigh PN et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology 47(6 Suppl. 4), S242.S250 (1996).
85. Vorwerk CK, Zurakowski D, McDermott LM, Mawrin C, Dreyer EB. Effects of axonal injury on ganglion cell survival and glutamate homeostasis. Brain Res. Bull. 62(6), 485.490 (2004).
86. Ettaiche M, Fillacier K, Widmann C, Heurteaux C, Lazdunski M. Riluzole improves functional recovery after ischemia in the rat retina. Invest. Ophthalmol. Vis. Sci. 40(3), 729.736 (1999).
87. Calzada JI, Jones BE, Netland PA, Johnson DA. Glutamate-induced excitotoxicity in retina: neuroprotection with receptor antagonist, dextromethorphan, but not with calcium channel blockers. Neurochem. Res. 27(1.2), 79.88 (2002).
88. Bakalash S, Shlomo GB, Aloni E et al. T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure. J. Mol. Med. 83(11), 904.916 (2005).
89. Blair M, Pease ME, Hammond J et al. Effect of glatiramer acetate on primary and secondary degeneration of retinal ganglion cells in the rat. Invest. Ophthalmol. Vis. Sci.46(3), 884.890 (2005).
90. Schwartz M. Modulating the immune system: a vaccine for glaucoma? Can. J. Ophthalmol. 42(3), 439.441 (2007).
91. Ben Simon GJ, Bakalash S, Aloni E, Rosner M. A rat model for acute rise in intraocular pressure: immune modulation as a therapeutic strategy. Am. J. Ophthalmol. 141(6), 1105.1111 (2006).
92. Ishii Y, Kwong JM, Caprioli J. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest. Ophthalmol. Vis. Sci. 44(5), 1982.1992 (2003). (Pubitemid 36520289)
93. Chen TA, Yang F, Cole GM, Chan SO. Inhibition of caspase.3-like activity reduces glutamate induced cell death in adult rat retina. Brain Res. 904(1), 177.188 (2001).
94. Seki M, Soussou W, Manabe SI, Lipton SA. Caspase substrate-binding peptide IQACRG protects rat retinal ganglion cells from N-methyl-d-aspartate receptormediated excitotoxicity. Invest. Ophthalmol. Vis. Sci. 51(2), 1198.1207 (2010).
95. Laengle UW, Trendelenburg AU, Markstein R, Nogues V, Provencher.Bollinger A, Roman D. GLC756 decreases TNF.a via an a2 and b2 adrenoceptor related mechanism. Exp. Eye Res. 83(5), 1246.1251 (2006).
96. Laengle UW, Markstein R, Pralet D, Seewald W, Roman D. Effect of GLC756, a novel mixed dopamine D1 receptor antagonist and dopamine D2 receptor agonist, on TNF.a release in vitro from activated rat mast cells. Exp. Eye Res. 83(6), 1335.1339 (2006).
97. McKernan DP, Guerin MB, O'Brien CJ, Cotter TG. A key role for calpains in retinal ganglion cell death. Invest. Ophthalmol. Vis. Sci. 48(12), 5420.5430 (2007).
98. Oka T, Tamada Y, Nakajima E, Shearer TR, Azuma M. Presence of calpaininduced proteolysis in retinal degeneration and dysfunction in a rat model of acute ocular hypertension. J. Neurosci. Res. 83(7), 1342.1351 (2006).
99. Chiu K, Lam TT, Ying Li WW, Caprioli J, Kwong Kwong JM. Calpain and N-methyld- aspartate (NMDA)-induced excitotoxicity in rat retinas. Brain Res. 1046(1.2), 207.215 (2005).
100. Tamada Y, Nakajima E, Nakajima T, Shearer TR, Azuma M. Proteolysis of neuronal cytoskeletal proteins by calpain contributes to rat retinal cell death induced by hypoxia. Brain Res. 1050(1.2), 148.155 (2005).
101. Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch. Ophthalmol. 127(4), 402.406 (2009).
102. Chao HM, Chidlow G, Melena J, Wood JP, Osborne NN. An investigation into the potential mechanisms underlying the neuroprotective effect of clonidine in the retina. Brain Res. 877(1), 47.57 (2000).
103. Lonngren U, Napankangas U, Lafuente M et al. The growth factor response in ischemic rat retina and superior colliculus after brimonidine pre-treatment. Brain Res. Bull. 71(1.3), 208.218 (2006).
104. Wheeler L, WoldeMussie E, Lai R. Role of a-2 agonists in neuroprotection. Surv. Ophthalmol. 48(Suppl. 1), S47.S51 (2003).
105. Donello JE, Padillo EU, Webster ML, Wheeler LA, Gil DW. a(2)-adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J. Pharmacol. Exp. Ther. 296(1), 216.223 (2001).
106. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA. A2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest. Ophthalmol. Vis. Sci. 49(10), 4515.4522 (2008).
107. Vidal L, Diaz F, Villena A, Moreno M, Campos JG, Perez de Vargas I. Reaction of Muller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine. Brain Res. Bull. 82(1.2), 18.24 (2010).
108. Hernandez M, Urcola JH, Vecino E. Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments. Exp. Eye Res. 86(5), 798.806 (2008).
109. Newman NJ, Biousse V, David R et al. Prophylaxis for second eye involvement in leber hereditary optic neuropathy: an open-labeled, nonrandomized multicenter trial of topical brimonidine purite. Am. J. Ophthalmol. 140(3), 407.415 (2005).
110. Wilhelm B, Ludtke H, Wilhelm H. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3.month, double-masked, randomised, placebocontrolled trial. Graefes Arch. Clin. Exp. Ophthalmol. 244(5), 551.558 (2006).
111. Krupin T, Liebmann JM, Greenfield DS, Rosenberg LF, Ritch R, Yang JW. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology 112(3), 376.385 (2005).
112. + channels: comparison with other b-adrenoceptor antagonists. Br. J. Pharmacol. 130(4), 759.766 (2000).
113. Melena J, Stanton D, Osborne NN. Comparative effects of antiglaucoma drugs on voltage-dependent calcium channels. Graefes Arch. Clin. Exp. Ophthalmol. 239(7), 522.530 (2001).
114. Wood JP, DeSantis L, Chao HM, Osborne NN. Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA. Exp. Eye Res. 72(1), 79.86 (2001).
115. Harris A, Arend O, Kagemann L, Garrett M, Chung HS, Martin B. Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. J. Ocul. Pharmacol. Ther. 15(3), 189.197 (1999).
116. Kniep EM, Roehlecke C, Ozkucur N et al. Inhibition of apoptosis and reduction of intracellular pH decrease in retinal neural cell cultures by a blocker of carbonic anhydrase. Invest. Ophthalmol. Vis. Sci. 47(3), 1185.1192 (2006).
117. Seki M, Tanaka T, Matsuda H et al. Topically administered timolol and dorzolamide reduce intraocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model. Br. J. Ophthalmol. 89(4), 504.507 (2005).
118. Schuettauf F, Quinto K, Naskar R, Zurakowski D. Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model. Vision Res. 42(20), 2333.2337 (2002).
119. Kerrigan-Baumrind LA, Quigley HA, Pease ME, Kerrigan DF, Mitchell RS. Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. Invest. Ophthalmol. Vis. Sci. 41, 741.748 (2000).